Mark Erlander compensation by year
Cardiff Oncology Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $398,729 | $444,764 | $532,716 | $570,600 | $594,400 | $610,584 | $635,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $255,622 | $476,380 | $2,851,972 | $753,272 | $672,978 | $1,471,762 | $2,266,106 |
| Non-equity incentive | $198,600 | $229,559 | $250,510 | $266,475 | $280,394 | $319,030 | $122,238 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total | $852,951 | $1,150,703 | $3,635,198 | $1,590,347 | $1,547,772 | $2,401,376 | $3,023,344 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cardiff Oncology, Inc. DEF 14A filed April 23, 2026, accession 0001213037-26-000006, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Cardiff Oncology, Inc. filed document, accession 0001213037-26-000006. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 150,645 | — | $1.72 |
| Option | 23,133 | — | $2.50 |
| Option | 286,875 | — | $3.51 |
| Option | 758,400 | — | $3.58 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Cardiff Oncology, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Cardiff Oncology’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mark Erlander · this page | Chief Executive Officer | $3,023,344 |
| Roger Sidhu | Chief Medical Officer | $2,273,805 |
| James Levine | Chief Financial Officer | $1,545,615 |
Board service
Cardiff Oncology board · FY2023–FY2024How this board is paid
Company policy: Cardiff Oncology pays directors a $65,000 cash retainer and $56,460 in Options. As stated in Cardiff Oncology's FY2024 proxy.
The full Cardiff Oncology compensation record
free company briefThis page is one person within Cardiff Oncology's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Cardiff Oncology proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Cardiff Oncology's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cardiff Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order CRDF
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.